In Brief
This article was originally published in The Tan Sheet
Executive Summary
EC waives GMP documentation for U.S. APIs; MHRA restricts codeine use; organic selenium urged for infant formula; NBTY agrees to settle glucosamine class action; currant products dubbed drugs; FDA warns about more spiked supplements; retailer recalls DMAA products; more news In Brief.
You may also be interested in...
In Brief
FDA seeks DMAA product seizure; skin tag remover study flawed – ERSP; Plan B One-Step approved fully OTC; FDA continues evaluating laxative TEA; FDA hosts supply chain public hearing; energy drink marketing to youths challenged; more news In Brief.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.